$41.7 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO's 25 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 70.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TXN | Buy | TEXAS INSTRUMENTS INC | $13,034,000 | +429.4% | 145,400 | +354.4% | 31.22% | +326.6% |
| WPZ | WILLIAMS PARTNERS LPlp - public equity | $6,719,000 | -3.0% | 172,732 | 0.0% | 16.09% | -21.9% | |
| VEA | Sell | VANGUARD FTSE DEV MKTSetfs | $3,274,000 | -4.1% | 75,430 | -8.7% | 7.84% | -22.7% |
| VOO | Sell | VANGUARD 500 INDEX FUNDetfs | $2,872,000 | -5.6% | 12,446 | -9.1% | 6.88% | -23.9% |
| VOE | Sell | VANGUARD MID-CAP VALUE ETFetfs | $2,870,000 | -4.4% | 27,165 | -6.9% | 6.88% | -22.9% |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $2,588,000 | +28.1% | 524,929 | 0.0% | 6.20% | +3.2% | |
| VWO | Sell | VANGUARD MSCI EMERGING MKTSetfs | $2,529,000 | -3.7% | 58,049 | -9.8% | 6.06% | -22.4% |
| BPTH | BIO-PATH HOLDINGS INC | $1,379,000 | -5.3% | 3,830,882 | 0.0% | 3.30% | -23.7% | |
| VDE | Buy | VANGUARD ENERGY ETFetfs | $1,102,000 | +21.4% | 11,781 | +14.8% | 2.64% | -2.2% |
| GMOLQ | GENERAL MOLY INC | $1,096,000 | +1.5% | 2,922,831 | 0.0% | 2.62% | -18.2% | |
| MGEN | MIRAGEN THERAPEUTICS INC | $965,000 | -29.3% | 105,465 | 0.0% | 2.31% | -43.0% | |
| VNQ | Buy | VANGUARD REIT ETFetfs | $829,000 | +8.4% | 9,978 | +8.6% | 1.99% | -12.7% |
| APEN | APOLLO ENDOSURGERY INC | $722,000 | -40.7% | 154,301 | 0.0% | 1.73% | -52.2% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $439,000 | -25.2% | 35,714 | 0.0% | 1.05% | -39.7% | |
| PLXP | PLX PHARMA INC | $403,000 | +4.7% | 62,673 | 0.0% | 0.96% | -15.6% | |
| CMA | New | COMERICA INC. | $343,000 | – | 4,510 | +100.0% | 0.82% | – |
| IVZ | New | INVESCO LTD | $207,000 | – | 5,900 | +100.0% | 0.50% | – |
| RETA | New | REATA PHARMACEUTICALS INC | $166,000 | – | 5,322 | +100.0% | 0.40% | – |
| FGEN | New | FIBROGEN, INC | $61,000 | – | 1,133 | +100.0% | 0.15% | – |
| INSW | New | INTERNATIONAL SEAWAYS INC | $59,000 | – | 3,000 | +100.0% | 0.14% | – |
| CIM | New | CHIMERA INVESTMENT CORP | $57,000 | – | 3,000 | +100.0% | 0.14% | – |
| IWP | New | ISHARES TR RUSSELL MIDCAP GROWTH INDetfs | $25,000 | – | 224 | +100.0% | 0.06% | – |
| POR | PORTLAND GENERAL ELECTRIC CO | $5,000 | 0.0% | 118 | 0.0% | 0.01% | -20.0% | |
| BA | New | BOEING CO | $2,000 | – | 6 | +100.0% | 0.01% | – |
| PEP | New | PEPSICO INC | $2,000 | – | 20 | +100.0% | 0.01% | – |
| DISCA | Exit | DISCOVERY COMMUNICATIONS | $0 | – | -115 | -100.0% | -0.01% | – |
| JNJ | Exit | JOHNSON & JOHNSON | $0 | – | -47 | -100.0% | -0.02% | – |
| DISCK | Exit | DISCOVERY COMMUNICATIONS INC., SERIES C | $0 | – | -290 | -100.0% | -0.02% | – |
| MON | Exit | MONSANTO CO | $0 | – | -515 | -100.0% | -0.18% | – |
| PK | Exit | PARK HOTELS & RESORTS INCfunds, real estate investment trusts, domestic | $0 | – | -9,587 | -100.0% | -0.77% | – |
| JNCE | Exit | JOUNCE THERAPEUTICS INC | $0 | – | -30,488 | -100.0% | -1.27% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS INC | $0 | – | -17,800 | -100.0% | -1.45% | – |
| XOM | Exit | EXXON MOBIL CORPORATION | $0 | – | -14,000 | -100.0% | -3.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-04 |
| 3 | 2023-06-02 |
| 13F-HR | 2023-05-22 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-04 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.